Xbrane Biopharma (Sweden) Today
| XBRANE Stock | SEK 0.19 0.01 5.00% |
Performance4 of 100
| Odds Of DistressLess than 10
|
Xbrane Biopharma is trading at 0.19 as of the 23rd of November 2024, a 5 percent decrease since the beginning of the trading day. The stock's open price was 0.2. Xbrane Biopharma has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Xbrane Biopharma AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of May 2024 and ending today, the 23rd of November 2024. Click here to learn more.
Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. The company has 27.51 M outstanding shares. More on Xbrane Biopharma AB
Moving against Xbrane Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Xbrane Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Xbrane Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Xbrane Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
Xbrane Biopharma AB (XBRANE) is traded on Stockholm Exchange in Sweden and employs 74 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.74 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Xbrane Biopharma's market, we take the total number of its shares issued and multiply it by Xbrane Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Xbrane Biopharma operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 27.51 M outstanding shares.
Xbrane Biopharma AB has accumulated about 44.32 M in cash with (219.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Xbrane Biopharma Probability Of Bankruptcy
Ownership AllocationXbrane Biopharma AB retains a total of 27.51 Million outstanding shares. Xbrane Biopharma owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Xbrane Ownership Details
Xbrane Biopharma Risk Profiles
Although Xbrane Biopharma's alpha and beta are two of the key measurements used to evaluate Xbrane Biopharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.72 | |||
| Semi Deviation | 4.5 | |||
| Standard Deviation | 6.51 | |||
| Variance | 42.42 |
Xbrane Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Xbrane Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
| All Next | Launch Module |
Xbrane Biopharma Corporate Management
Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nina Ivers | Head HR | Profile | |
| Maria Edebrink | Head Assurance | Profile | |
| Dina Jurman | Head of Clinical Affairs | Profile | |
| Anette Lindqvist | CFO Relations | Profile | |
| Martin mark | Chief Officer | Profile | |
| David Vikstrm | Chief Officer | Profile |
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.